News & Updates
–JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline…
U.S. pivotal trial to assess efficacy and safety of AURN001 compared to placebo Potential first-in-class cell therapy to regenerate corneal clarity and restore vision with a single procedure Excerpt from the Press Release: SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and…
Financing co-led by Frazier Life Sciences and Novartis Venture Fund with significant participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund and Astellas Venture Management Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment…
Custom Validated Development Services Our Custom Validated Development services adds significant value to our Electronic Data Capture (EDC) and integrated Imaging Workflow platform by ensuring the system is integrated with all of your clinical software and devices. Rather than relying solely on standard configurations, custom validated development enables sponsors and CROs to grow into our…
Meet with Christopher Kata, Director of Sales & Marketing and Nick Travers May 3rd – 6th at the SCDM EMEA meeting being held in Copenhagen, Denmark! If you’re attending be sure to to reach out to Christopher and Chris to schedule a one on meeting or just drop by booth at your convenience! We’re looking…
Excerpt from the Press Release: SAN DIEGO, April 7, 2026 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer…
Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with…
Excerpt from the Press Release: A potential weakness in a common form of leukemia could lead to new treatments. The discovery, made by researchers at the Lewis Katz School of Medicine at Temple University, shows that leukemia cells with mutations in DNMT3A—a gene often altered in acute myeloid leukemia (AML)—depend on a DNA-repair enzyme known as DNA polymerase…
Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients…
Company Announces First Patient Enrolled in CLEAR-IT Study Evaluating Symphony and Prodigy Thrombectomy Systems for Vascular Disease Excerpt from the Press Release: CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the enrollment of the first patient in the CLEAR-IT Study, a prospective,…
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?